CAMI WICKSTROM: Open Payments
NPI 1255003273 · OMAHA, NE. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$562 in 15 payments from 10 companies in 2025. Trend: 2023 $249 · 2024 $135 · 2025 $562
Food & beverage: $562
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 4 | $161 |
| AstraZeneca Pharmaceuticals LP | 1 | $120 |
| Ardelyx, Inc. | 1 | $119 |
| Sumitomo Pharma America, Inc. | 2 | $42 |
| Lilly USA, LLC | 2 | $34 |
| PFIZER INC. | 1 | $21 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $19 |
| Janssen Pharmaceuticals, Inc | 1 | $16 |
| Novo Nordisk Inc | 1 | $15 |
| Axsome Therapeutics, Inc. | 1 | $14 |
Products named: FASENRA, IBSRELA, QULIPTA, VRAYLAR, GEMTESA, JARDIANCE, VYNDAQEL, CAPLYTA.
Industry payments across NE — which companies pay providers there.
